Lund, Sweden, 8 January 2019 – Xintela announces today that the company's international (PCT) patent application for quality-assured chondrocytes (cartilage cells), developed using the company's integrin markers, was published on January 3, 2019 under publication number WO 2019/002547.
The patent application relates to a further development of Xintela's marker technology and quality test XACT and protects chondrocyte preparations of high-quality and purity as well as methods to isolate chondrocytes using a combination of the cell markers integrin a10b1 and integrin a11b1. Chondrocytes, quality assured with Xintela's quality assay XACT have both regulatory and functional advantages in cell therapy of cartilage damage. The European Patent Office (EPO), which has examined the international patent application, has concluded that it is both novel and inventive.
“This patent application demonstrates our proactive approach to create strong and long-term protection of our portfolio technologies and importantly, it also strengthens our position in collaboration discussions with companies that develop chondrocyte products. The positive examination report from the EPO is very promising, not least considering that the national patent authorities in many other territories tends to follow the opinion of the EPO in their assessments”, says Xintela's CEO Evy Lundgren-Åkerlund.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
223 81 Lund
Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company’s oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO